{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-006657","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2022-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.136908+00:00","generated_at":"2026-06-25T16:42:22.017923+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Edesa Biotech Q2 net loss $4.57M ($0.33/shr) on lower R&D spend; clinical trials advancing","bullets":["Net loss $4.57M for quarter ended Mar 31, 2022 vs $2.26M year ago; R&D expenses fell $4.94M to $3.04M.","Six-month net loss $8.95M ($0.66/shr) vs $4.90M ($0.45/shr); raised ~$11.6M via ATM and direct investment.","Working capital $14.66M; cash and equivalents $15.89M at quarter end.","Phase 3 ARDS trial >25% randomized; approvals in Canada, Poland, Colombia; U.S. design discussions ongoing.","Phase 2b allergic contact dermatitis study 75% enrolled; completion expected Q4 2022, topline data early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-006657","json":"https://secwatch.observer/filing/0001654954-22-006657.json","markdown":"https://secwatch.observer/filing/0001654954-22-006657.md","text":"https://secwatch.observer/filing/0001654954-22-006657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000165495422006657/0001654954-22-006657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000165495422006657/edsa_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T16:42:22.017923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}